IFNG and neoplasm: These accessory transgenes overcome the limitations of CAR T cell therapy by preventing checkpoint inhibition, supporting T cell function, promoting TH1 polarisation, and maintaining these populations in the presence of IFNγ, while combatting tumour heterogeneity by targeting additional TAA [124].